


# **22<sup>nd</sup> Working Group Meeting of the Scandinavian Sarcoma Group**

January 22-23, 2018  
Malmö



**PROGRAM**

[www.ssg-org.net](http://www.ssg-org.net)

# Introduction

---

Welcome to the 22<sup>nd</sup> Scandinavian Sarcoma Group Working Committee Meeting in Malmö 2018. As usual all working committees have their own program and will discuss comprehensively selected topics. On Tuesday afternoon the Visceral and retroperitoneal sarcoma working group will have their own meeting (as previous years).

At the General assembly Monday morning there will be no election this year, but the coming election on WGM December 2018 will be discussed. New chairman, secretary and treasurer are to be elected December 2018. The SSGs meetings in the future are important tasks that will be discussed.

Results of SSG XX, the adjuvant STS trial will be presented. Due to abstract for CTOS, November 2017, a presentation of data at the SSG 38<sup>th</sup> Plenary Meeting in Aarhus, September 2017, could not be presented.

As previous years a project (AYA project) using the data of the Central register will be given.

Other tasks on the agenda are imaging diagnostics of soft tissue sarcoma and the updated version of the ESMO guidelines.

Our colleagues from Bergen will inform us about the program for the 40 years Jubilee Meeting (39<sup>th</sup> SSG Plenary Meeting) in Bergen May 8-10, 2019. Deadline for abstracts March 1<sup>st</sup>, 2019.

Notably, our Scandinavian multidisciplinary cooperation is central in maintaining a high quality of diagnosis, treatment and follow-up of patients with bone- and soft tissue sarcoma. We should therefore strengthen such cooperation in the future.

All chairmen of the working committees should send their report from the meeting to the SSG's secretariat, our administrative secretary Eva-Mari Olofsson (Eva-Mari.Olofsson@med.lu.se) before February 15<sup>th</sup>, 2018.

Kirsten Sundby Hall, Chairman

Mikael Eriksson, secretary  
Scandinavian Sarcoma Group

# Content

---

<b>Introduction</b> .....	2
<b>Program</b>	
Sunday January 21, 2018.....	4
Monday January 22, 2018 .....	5
Tuesday January 23, 2018 .....	6
<b>Working group meetings</b>	
Orthopaedic surgery working group.....	7-8
Imaging working group .....	9
Medical oncology & Radiotherapy working groups .....	10
Morphology/Tumor biology working group .....	11-12
Nurses and Physiotherapists working group.....	13
Central register working group.....	14
Visceral and retroperitoneal sarcoma working group.....	15

**Sunday January 21, 2018**

---

**17.00–19.00 Board meeting, Park Inn**

## Monday January 22, 2018

---

08.00–08.30 *Registration in Tokyo, WTC*

**08.30–12.00 Joint meeting**, Meeting room: WTC “Tokyo”  
**Chairmen:** *K. Sundby Hall, Oslo, M. Eriksson, Lund*

08.30 General assembly

- SSG meetings in the future – How? When? Why?
- Constitution of the Bergen Plenary meeting organization committee
- SSG economy
- The work of the election committee
- Other questions

09.45 *Coffee*

10.15 SSG XX  
*K. Sundby Hall, Oslo*

10.40 ESMO guidelines, the new version of 2017.  
*M. Eriksson, Lund, K. Sundby Hall, Oslo*

11.05 EUROBOSS: published results so far.  
*K. Sundby Hall, Oslo*

11.30 Soft tissue sarcoma in adolescents and young adults in Scandinavia – a register study.  
*K. Papworth, Umeå*

11.50 Imaging diagnostics of soft tissue sarcoma: Anything new?  
*O. Angetete, Trondheim*

12.15 The SSG 40 years Jubilee Meeting in Bergen 2019 – Information so far  
*By the Organization committee*

12.45 *Lunch (Restaurant Novel at WTC)*

**13.45–19.00 SSG working group meetings**

20.00 *Dinner, Restaurant Novel at WTC*

## Tuesday January 23, 2018

---

08.00–08.30 *Registration in Tokyo, WTC*

08.00-10.00 SSG Central register group  
Meeting room: Hotel Park Inn “Conference room C”

**08.30–11.00 Cont. SSG working group meetings**

10.30 *Coffee*

**11.00–12.45 Joint meeting**, Meeting room: WTC “Tokyo”  
**Chairman:** *K. Sundby Hall, Oslo*

### **Reports from all groups**

SSG Morphology/Tumor biology group  
*J. Wejde, Stockholm*

SSG Orthopaedic surgery group  
*H, Jónsson jr, Reykjavik*

SSG Imaging group  
*O. Angenete, Trondheim*

SSG Medical oncology & Radiotherapy group  
*K. Boye, Oslo, N. Jebsen, Bergen*

SSG Nurse and Physiotherapists group  
*C. Våde, Oslo*

SSG Central register group  
*E. Styring, Lund*

12.45–13.45 *Lunch (Restaurant Novel at WTC)*

**13.45–17.00 SSG Visceral and retroperitoneal sarcoma working group**

Meeting room: WTC “Tokyo”

## Orthopaedic surgery working group

---

**Date:** January 22, 2018, 13.30–19.00  
January 23, 2018, 08.30–11.00

**Place:** Meeting room: WTC “Shanghai”

**Chairman:** *H, Jónsson jr, Reykjavik*

### Agenda

- **The sarcoma pathway:**

What are we actually achieving by making high-priority of the referral pattern in sarcoma suspect diagnosis?

- does delay during the diagnostic procedure affect life expectancy?

- are we fighting with tumor biology or fighting for good looking time frames!

What variables are to be used in the registration or referrals to a sarcoma center (date of tumor symptom.....date of treatment?)

Who should be responsible for this pathway to work properly in reality: a doctor, a study nurse or...?

- **During the last 5 years, Iceland has sudden increase in Ewing sarcomas!**

Is there (should it be) someone who has his eye on abnormalities in our common sarcoma registry and makes notice to deviations compared to the other countries?

- **How can we talk about a sarcoma registry** if we are only dealing with the extremities and the trunk wall and not the head and neck, the retroperitoneum and uterus, the children?

- **Our home pages are very different!**

As we are always trying to synchronize our treatment strategies, why not synchronize our:

1. Regimes and principles before and after?
2. Information to patients and families?
3. Information to authorities?

- **Local tumor control in Ewing sarcoma: surgery and/or radiotherapy?**
- **Surgical treatment vs radiotherapy in Ewing sarcoma of scapula.**
- **Rationale of non surgical treatment in metastatic bone lesions.**
- **Bone reconstruction with pretreatment of autograft can be done in various ways, both in handling(cryo-radio- or autoclave) and with different timeframes.**  
Can we find a common solution – i.e. guidelines?
- **Has the discrepancy in size of STS between imaging and specimen clinical relevance in life expectancy?**
- **What do we know for sure about intra-operative ST tumor rupture?!**
  - what does it mean?
  - does it affect the treatment schedule?
  - does it affect life expectancy?
- **How reliable is post-chemo reduction in tumor zone as a reference for save surgical margin?**
- **Case reports from colleagues that have been presented and discussed through the Internet!**

## Imaging working group

---

**Date:** January 22, 2018, 13.30–19.00  
January 23, 2018, 08.30–11.00

**Place:** Meeting room: WTC “Abu Dhabi”

**Chairman:** *O. Angenete, Trondheim*

### Agenda

- Is there an interest amongst radiologists for to inform each other on a yearly basis on the diagnostic different groups of sarcoma?
- Li Fraumeni syndrome. Experiences, modalities and intervals for follow-up?
- Open discussion on MR protocols for soft tissue sarcoma.
- Experiences on imaging work-up of sarcoma patients before referral to your sarcoma center. Is it adequate? If not, what can we do about it?
- Case reports! Always something to learn.....
- Time allowing, emerging techniques “HyperPET”.

## **Medical oncology & Radiotherapy working group**

---

**Date:** January 22, 2018, 13.30–19.00  
January 23, 2018, 08.30–11.00

**Place:** Meeting room: WTC “Tokyo”

**Chairmen:** *K. Boye, Oslo, N. Jebsen, Bergen*

### **Agenda**

- Radiotherapy and immunotherapy: synergism, abscopal effects and clinical trials in sarcoma.
- Localized Ewing sarcoma; chemotherapy protocols and local therapy.
- Adjuvant chemotherapy in localized soft tissue sarcoma. Details from the SSG XX study and further discussions.
- Possible SSG studies on the prognostic and predictive value of serum biomarkers in sarcoma.
- What’s new? Novel therapies for sarcomas.
- ESMO guidelines. Follow-up of the discussions in the plenary session.
- Short study updates.

## Morphology/Tumor biology working group

---

- Date:** January 22, 2018, 13.30–19.00  
January 23, 2018, 08.30–11.00
- Place:** Meeting room: WTC “Curacao”
- Chairman:** *J. Wejde, Stockholm, K, Hansén Nord, Lund*

### Agenda

- Review meetings – when and where?
- Review meetings – additional benefits
  - ❖ Cases that are difficult to classify – could they be analyzed for genetic aberrations?
  - ❖ Rewiewed series – would it be beneficial to add genetic information?
- There is an ongoing process to accredit hospital laboratories, also pathology. An important issue is the possibility to have some type of accreditation of given diagnoses. This is often done by either exchanging cases between accredited laboratories e.g. Equalis. For sarcomas, there are natural hurdles to ensure this type of activity within each of the countries in SSG, but could this be achieved if we exchanged cases between laboratories in the Nordic countries?
- Evaluation of response after neoadjuvant treatment, chemo- and radiotherapy. Guidelines to be used in the Nordic countries.
  - Recent references: Wardelmann E, et al. Eur J Cancer. 2016; 53:84-95.
  - Schaefer IM, et al. Int j Radiat Oncol Biol Phys. 2017; 98:375-383.
- Standardization of pathology reports – possible to adapt developed proformas from CAP, RCPATH etc?

- Revision and update of documents pertaining to pathology/tumor biology on the SSG homepage – should we make an effort?

## Nurses and Physiotherapists working group

---

- Date:** January 22, 2018, 13.30–19.00  
January 23, 2018, 08.30–11.00
- Place:** Meeting room: WTC “New York”
- Chairman:** *C. Våde, Oslo*

### Agenda

- Sarcoma knows no borders, neither should Nursing and Supplemental Care.
- The male cancer patient and communication.
- From conference to reality.
- Mentorship program för patients treated for sarcoma
- Meetingpoint for children and young adults, during and after treatment.
- Conversations before discharge from hospital.
- Amputations and physiotherapy.
- Evaluation of the distress thermometer as a tool for the need for cancer rehabilitation.

## Central register working group

---

**Date:** January 23, 2018, 08.00–10.00

**Place:** Meeting room: Hotel Park Inn “Conference room C”

**Chairman:** *E. Styring, Lund*

### Agenda

- The annual report, comments and suggestions for next year.
- National registry protocols, are our variables matching?  
Work needed?
- Contact persons for each center?
- Differences between the centers and countries in various variables?
- Other topics

## **Visceral and retroperitoneal sarcoma working group**

---

**Date:** January 23, 2018, 13.45–17.00

**Place:** Meeting room: WTC “Tokyo”

**Chairmen:** *J. Åhlén, Stockholm, T. Hølmekbakk, Oslo*

### **Agenda**

- The value of EUS and KIT/PDGFRA sequencing in neoadjuvant imatinib for GIST.
- Neoadjuvant imatinib for GIST: proposal for a clinical trial.
- Adjuvant imatinib after surgery for GIST with tumour rupture. Discussion of available data and current practice.
- Adjuvant imatinib in high-risk patients without tumour rupture. Discussion of available data and current practice.
- Up-date on on-going GIST trials.









**World Trade Center Malmö**

Jungmansgatan 12  
SE-211 19 Malmö  
Phone: +46 40 627 11 00  
E-mail: info@wtcmalmo.se

**Park Inn by Radisson Malmö Hotel**

Sjömansgatan 2  
SE-211 19 Malmö  
Phone: +46 40 628 6000  
E-mail: info.malmo@rezidorparkinn.com

**Scandinavian Sarcoma Group  
SSG secretariat**

Lund University  
Institution of Clinical Sciences  
Department of Cancer Epidemiology  
Kamprad 5th floor, Barngatan 4  
SE-221 85 Lund  
E-mail: Eva-Mari.Olofsson@med.lu.se  
ssg@med.lu.se  
Web: [www.ssg-org.net](http://www.ssg-org.net)